Home > Products > CD8 & PSCA > Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (IgG-Fv)

Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (IgG-Fv)  (BSGV-131)

Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD8 antibody variable domain is fused to the C terminal of an IgG of anti-PSCA antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Specifications

Targets
CD8 & PSCA
Type
IgG-Fv
Species Reactivity
Human
Target 1
CD8
Host Animal 1
Mouse
Target 2
PSCA
Host Animal 2
Mouse
Application
FuncS; Promising therapeutic agent
Related Disease
Prostate cancer

Targets

Target 1
CD8
Gene ID
UniProt ID
Alternative Names
CD8A; CD8a molecule; Cluster of differentiation 8; CD8; MAL; p32; Leu2
Target 2
PSCA
Gene ID
UniProt ID
Alternative Names
PSCA; prostate stem cell antigen; PRO232

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD8 x Anti-PSCA Bispecific Antibody (IgG-Fv) (BSGV-131). Click the button below to contact us or submit your feedback about this product.

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY
Related products of "CD8 & PSCA"
See other bsAb targets related to "CD8"

See other bsAb targets related to "PSCA"

Online Inquiry

24x7 Service quality
USA

Tel:
Fax:
Email:

UK

Tel:
Email:

Germany

Tel:
Email: